Azur Pharma and Burren Pharmaceuticals acquired product rights to Gastrocrom UCB Pharmaceuticals

Jan. 2006

Client: Burren Pharmaceuticals and Azur Pharma are specialty pharmaceutical companies with a primary focus on the acquisition of marketed prescription pharmaceuticals

Role: Edgemont Partners acted as exclusive financial advisor to Burren Pharmaceuticals in the partnering of its exclusive rights to acquire Gastrocrom from UCB Pharma with Azur Pharma

Location: Philadelphia, PA

Sector: Pharmaceutical Services

Lead Banker: David Blume

View Press Release